Imanaka, Takahiro
Fujii, Kenichi http://orcid.org/0000-0002-1509-6071
Tanaka, Takamasa
Yanaka, Koji
Kimura, Toshio
Yoshihara, Nagataka
Miki, Kojiro
Kawai, Kenji
Akahori, Hirokuni
Kawakami, Rika
Hao, Hiroyuki
Hirota, Seiichi
Ishihara, Masaharu
Article History
Received: 25 October 2021
Accepted: 13 March 2022
First Online: 8 August 2022
Ethics declarations
:
: Takahiro Imanaka has nothing to declare for this study. Masaharu Ishihara received research fund from Amgen Inc. (Japan), and lecture fees from Bayer Yakuhin, Ltd. (Japan), Daiichi Sankyo Company (Japan), Nippon Boehringer Ingelheim Co., Ltd. (Japan), and Otsuka Pharmaceutical Co., Ltd. (Japan), and scholarship funds from Abbott Co.,Ltd. (Japan), Otsuka Pharmaceutical Co.,Ltd. (Japan), MID,Inc. (Japan), Ono Pharmaceutical Co.,Ltd. (Japan), Orbusneich Medical K. K. (Japan), Kowa Pharmaceutical Co.,Ltd. (Japan), Mitsubishi Tanabe Pharma Corporation (Japan), Terumo Corporation (Japan), Nipro Corporation (Japan), Lifeline Co.,Ltd. (Japan), Bayer Yakuhin, Ltd. (Japan), Fukuda Denshi Co.,Ltd. (Japan), and Boston Scientific K.K. (Japan), and endowed departments from Abbott (Japan), Medtronic Japan Co., Ltd. (Japan), and Nippon Boehringer Ingelheim Co., Ltd. (Japan). No other potential conflicts of interest relating to this article were reported.
: The study protocol was approved by the Institutional Review Board of Hyogo College of Medicine (approval number 3766).